Copyright
©2014 Baishideng Publishing Group Inc.
World J Diabetes. Oct 15, 2014; 5(5): 651-658
Published online Oct 15, 2014. doi: 10.4239/wjd.v5.i5.651
Published online Oct 15, 2014. doi: 10.4239/wjd.v5.i5.651
Table 2 Dose adjustment of dipeptidyl peptidase 4 inhibitors in chronic kidney disease
| CKD | ||||
| CKD 1, 2 and 3a (Clcr > 50 mL/min) | CKD 3b (Clcr 30-50 mL/min) | CKD stage 4 (Clcr 15-30 mL/min) | CKD stage 5 (ESRD) | |
| Sitagliptin (Januvia) | √ (100 mg × 1) | 1/2 dose (50 mg × 1) | 1/4 dose (25 mg × 1) | 1/4 dose (25 mg × 1) |
| Vildagliptin (Galvus) | √ (50 mg × 2) | 50 mg × 1 | 50 mg (no experience) | |
| Saxagliptin (Onglyza) | √ (5 mg × 1) | 1/2 dose (2.5 mg × 1) | 1/2 dose (2.5 mg × 1) | 1/2 dose (2.5 mg × 1) |
| Linagliptin (Trajenta) | √ (5 mg × 1) | √ (5 mg × 1) | √ (5 mg × 1) | P (5 mg × 1) |
| Alogliptin (Nesina) | √ (25 mg × 1) | 1/2 dose (12.5 mg × 1) | 1/4 dose (6.25 mg × 1) | 1/4 dose (6.25 mg × 1) |
- Citation: Ioannidis I. Diabetes treatment in patients with renal disease: Is the landscape clear enough? World J Diabetes 2014; 5(5): 651-658
- URL: https://www.wjgnet.com/1948-9358/full/v5/i5/651.htm
- DOI: https://dx.doi.org/10.4239/wjd.v5.i5.651